135 results on '"Burgués, Octavio"'
Search Results
2. Tratamiento neoadyuvante en el cáncer de mama. El papel del patólogo
3. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
4. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study
5. Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?
6. MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer
7. Aurora kinases in ovarian cancer
8. The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
9. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
10. Sarcoma sinovial primario de mama
11. miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
12. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
13. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
14. High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
15. Acquired aggressive multisystemic disseminated lobular capillary haemangioma: a life threatening disorder
16. Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway
17. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer
18. An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer
19. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
20. Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?
21. Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers
22. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
23. Overexpression of the truncated form of High Mobility Group A proteins (HMGA2) in human myometrial cells induces leiomyoma-like tissue formation
24. Biphasic dermatofibrosarcoma protuberans with a labyrinthine plexiform high-grade fibrosarcomatous transformation
25. Abstract 1075: AXL is a potential druggable target in trastuzumab resistance in HER2+ breast cancer patients
26. The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
27. Patología de los tumores neuroblásticos: evaluación pronóstica. Experiencia del centro español de referencia de la SEOP para estudios biopatológicos del neuroblastoma (1992-2005)
28. Abstract PS7-71: Breast cancer fast-track programme to shorten time between initial symptoms, diagnosis and initiation of treatment. 10 years update
29. Abstract PS19-20: Identification of a novel two-microRNA signature for recurrence prediction in HER2 positive breast cancer
30. Abstract PS18-20: Frequency and spectrum of doublePIK3CAsomatic mutations in metastatic breast cancer patients
31. Hepatoid adenocarcinoma of the urinary bladder: An unusual neoplasm
32. MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
33. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
34. Abstract P6-03-05: AXL-HER2 dimer as mechanism of anti-HER2 acquired resistance in HER2 amplified brest cancer models: A new step towards precision medicine
35. HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
36. Additional file 5: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
37. Additional file 3: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
38. Additional file 1: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
39. Additional file 8: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
40. Additional file 6: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
41. Additional file 2: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
42. Additional file 7: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
43. Additional file 4: of A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
44. The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
45. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement
46. Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
47. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
48. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
49. Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
50. Differential expression of receptor activator of nuclear factor kappa B in healthy endometrium, ovarian endometrioma, and endometrioid ovarian cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.